Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Serina Therapeutics (SER) EPS (Weighted Average and Diluted) (2021 - 2025)

Serina Therapeutics (SER) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.31 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 14.81% to -$0.31 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.91 through Dec 2025, up 61.88% year-over-year, with the annual reading at -$1.91 for FY2025, 26.49% down from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.31 in Q4 2025 for Serina Therapeutics, up from -$0.45 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.51 in Q2 2024 to a low of -$9.5 in Q4 2022.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.94 across 5 years, with a median of -$0.07 in 2022.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 483.33% in 2023 and later tumbled 2790.0% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.0 in 2021, then tumbled by 373259.9% to -$9.5 in 2022, then surged by 101.68% to $0.16 in 2023, then tumbled by 268.75% to -$0.27 in 2024, then decreased by 14.81% to -$0.31 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for SER at -$0.31 in Q4 2025, -$0.45 in Q3 2025, and -$0.66 in Q2 2025.